Try a new search

Format these results:

Searched for:



Total Results:


Treatment of Pregabalin Toxicity by Hemodialysis in a Patient With Kidney Failure [Case Report]

Yoo, Lawrence; Matalon, Daniel; Hoffman, Robert S; Goldfarb, David S
Pregabalin is prescribed for neuropathic pain. We report the first case of pregabalin toxicity in a hemodialysis patient and her successful treatment with hemodialysis. The patient was a 30-year-old woman on long-term hemodialysis therapy who experienced significant myoclonus of the arms and legs when her dose of pregabalin was mistakenly increased. The drug has 3 properties that contribute to making it amenable to removal by hemodialysis: relatively low molecular weight (159.23 Da), relatively low volume of distribution (0.5 L/kg), and not bound to plasma proteins. We achieved hemodialysis clearance of 88.8 mL/min, which was associated with resolution of symptoms immediately after hemodialysis
PMID: 19493601
ISSN: 1523-6838
CID: 99296

Principles and techniques applied to enhance elimination

Chapter by: Goldfarb, David S; Matalon, Daniel
in: Goldfrank's toxicologic emergencies by Goldfrank LR; Flomenbaum N [Eds]
New York : McGraw-Hill, 2006
pp. 160-172
ISBN: 0071437630
CID: 458872

Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma

Lochow, Peter; Schwartzbard, Arthur; Guest, Judy; Ripps, Carolyn; Matalon, Daniel; Gambetta, Rosemary; Tunick, Paul A; Sedlis, Steven
Patients with protruding aortic atheroma containing mobile emboli are at risk for peripheral emboli and stroke. This risk may possibly be reduced by anticoagulation, but whether or not such patients have an increased prevalence of thrombotic risk factors has not been previously determined. Twenty-two patients were studied (11 with protruding thoracic aortic atheromas and superimposed mobile thrombi on transesophageal echocardiography were compared to 11 age-matched controls). The authors evaluated activated protein C resistance (APC-R) by measuring the prolongation of the partial thromboplastin time (PTT) in response to activated protein C (APC). Concentrations of fibrinogen, antithrombin III (AT III), factor II, factor V, and D-dimer were also determined in all patients. There was significant resistance to APC (a smaller prolongation in PTT) in patients with atheromas and thrombi. They also had significantly higher concentrations of factor II. Factor V and fibrinogen were higher, and AT III lower, in patients than in controls; however, these latter differences did not reach statistical significance. Patients with aortic atheroma and mobile thrombi may have an increased prevalence of thrombotic risk factors. There is significantly increased resistance to activated protein C in patients with protruding atheroma and mobile thrombi in their thoracic aorta. There was also a trend toward elevated fibrinogen, homocysteine, and apo (a) concentrations as well as lower antithrombin III concentrations in these patients
PMID: 12143947
ISSN: 0003-3197
CID: 32261